FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W98243944> ?p ?o ?g. }

• W98243944 endingPage "6044" @default.
• W98243944 startingPage "6044" @default.
• W98243944 abstract "6044 Background: Monoclonal antibodies (MAb), such as trastuzumab (TZ) and bevacizumab (BZ), have become an important yet expensive component of cancer treatment. The potential cost impact on health care budgets needs to be assessed in the context of its potential utilization. An estimate of the additional costs incurred by adopting TZ and BZ therapy in breast (BRC), lung (LUC) and colorectal (CRC) cancers was undertaken. Methods: The MAb costs per patient were estimated based on treatment indications, length of treatment, standard doses / schedules and local pharmacy data. Supportive medications, diagnostics and health resources utilization only required for the MAb therapy were also examined. This analysis was performed in Canadian dollars ($), and assumes complete drug delivery and uncomplicated cycles. Drug costs were based on average 2005 wholesale prices in Canada. The analysis took a direct payer perspective. We subsequently estimated the cost of MAb therapy per patient relative to the total costs of conventional cancer management without MAb therapy. Budget impact estimates on Canada’s health care system were then derived according to constructed schema, which accounts for absolute numbers of target patients and systemic therapy utilization. Results: The average costs of TZ per treated patient were $47,278 and $26,648 for adjuvant and metastatic BRC, respectively. For BZ, these were $47,250 and $38,500 for metastatic LUC and CRC, respectively. Other costs associated with MAb therapy were in the range of 3–6%. The predicted TZ drug costs in metastatic breast cancer were within 10% of the actual costs derived from pharmacy data. The potential life-time absolute costs to Canada’s health care system were approximately $118 million for TZ, and $262 million for BZ. This corresponds to an average of approximately 21% increase in the health care expenditure for BRC, LUC, and CRC. Conclusions: MAb therapy, such as TZ and BZ, may add a significant cost burden to Canada’s publicly funded health care system. The developed schema in this analysis may be of potential use to health care providers and policy makers in assessing the impact of MAb therapy on health care budgets. No significant financial relationships to disclose." @default.
• W98243944 created "2016-06-24" @default.
• W98243944 creator A5003558955 @default.
• W98243944 creator A5024419533 @default.
• W98243944 creator A5032910241 @default.
• W98243944 creator A5034781849 @default.
• W98243944 creator A5075317213 @default.
• W98243944 creator A5076934168 @default.
• W98243944 date "2006-06-20" @default.
• W98243944 modified "2023-09-26" @default.
• W98243944 title "The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: Can we afford it?" @default.
• W98243944 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.6044" @default.
• W98243944 hasPublicationYear "2006" @default.
• W98243944 type Work @default.
• W98243944 sameAs 98243944 @default.
• W98243944 citedByCount "6" @default.
• W98243944 crossrefType "journal-article" @default.
• W98243944 hasAuthorship W98243944A5003558955 @default.
• W98243944 hasAuthorship W98243944A5024419533 @default.
• W98243944 hasAuthorship W98243944A5032910241 @default.
• W98243944 hasAuthorship W98243944A5034781849 @default.
• W98243944 hasAuthorship W98243944A5075317213 @default.
• W98243944 hasAuthorship W98243944A5076934168 @default.
• W98243944 hasConcept C104863432 @default.
• W98243944 hasConcept C121608353 @default.
• W98243944 hasConcept C126322002 @default.
• W98243944 hasConcept C143998085 @default.
• W98243944 hasConcept C151730666 @default.
• W98243944 hasConcept C159654299 @default.
• W98243944 hasConcept C160735492 @default.
• W98243944 hasConcept C162324750 @default.
• W98243944 hasConcept C203014093 @default.
• W98243944 hasConcept C2775930923 @default.
• W98243944 hasConcept C2776694085 @default.
• W98243944 hasConcept C2777802072 @default.
• W98243944 hasConcept C2779343474 @default.
• W98243944 hasConcept C2779786085 @default.
• W98243944 hasConcept C50522688 @default.
• W98243944 hasConcept C512399662 @default.
• W98243944 hasConcept C530470458 @default.
• W98243944 hasConcept C542903549 @default.
• W98243944 hasConcept C71924100 @default.
• W98243944 hasConcept C86803240 @default.
• W98243944 hasConceptScore W98243944C104863432 @default.
• W98243944 hasConceptScore W98243944C121608353 @default.
• W98243944 hasConceptScore W98243944C126322002 @default.
• W98243944 hasConceptScore W98243944C143998085 @default.
• W98243944 hasConceptScore W98243944C151730666 @default.
• W98243944 hasConceptScore W98243944C159654299 @default.
• W98243944 hasConceptScore W98243944C160735492 @default.
• W98243944 hasConceptScore W98243944C162324750 @default.
• W98243944 hasConceptScore W98243944C203014093 @default.
• W98243944 hasConceptScore W98243944C2775930923 @default.
• W98243944 hasConceptScore W98243944C2776694085 @default.
• W98243944 hasConceptScore W98243944C2777802072 @default.
• W98243944 hasConceptScore W98243944C2779343474 @default.
• W98243944 hasConceptScore W98243944C2779786085 @default.
• W98243944 hasConceptScore W98243944C50522688 @default.
• W98243944 hasConceptScore W98243944C512399662 @default.
• W98243944 hasConceptScore W98243944C530470458 @default.
• W98243944 hasConceptScore W98243944C542903549 @default.
• W98243944 hasConceptScore W98243944C71924100 @default.
• W98243944 hasConceptScore W98243944C86803240 @default.
• W98243944 hasIssue "18_suppl" @default.
• W98243944 hasLocation W982439441 @default.
• W98243944 hasOpenAccess W98243944 @default.
• W98243944 hasPrimaryLocation W982439441 @default.
• W98243944 hasRelatedWork W144521535 @default.
• W98243944 hasRelatedWork W2048042444 @default.
• W98243944 hasRelatedWork W2073443344 @default.
• W98243944 hasRelatedWork W2095153339 @default.
• W98243944 hasRelatedWork W2401868633 @default.
• W98243944 hasRelatedWork W2410831480 @default.
• W98243944 hasRelatedWork W2411890706 @default.
• W98243944 hasRelatedWork W2587265631 @default.
• W98243944 hasRelatedWork W3200352014 @default.
• W98243944 hasRelatedWork W4238354881 @default.
• W98243944 hasVolume "24" @default.
• W98243944 isParatext "false" @default.
• W98243944 isRetracted "false" @default.
• W98243944 magId "98243944" @default.
• W98243944 workType "article" @default.